Clinical Trial

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2024 (before its estimated January 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JMT202 in Healthy Participants.
Protocol Amendment History 1 change
critical Trial status changed: Enrolling by Invitation → Unknown 2026-08-02
Trial Details
NCT Number NCT06564467
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Healthy Subjects
Enrollment 54 participants
Start Date 2024-07-23
Primary Completion 2025-01-10 (estimated)
Study Completion 2025-07-10 (estimated)
Updated on ClinicalTrials.gov 2024-08-22